Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 4Resectable Pancreatic Cancer 1Prostatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1Advanced Pancreatic Cancer 1Adenocarcinoma 1

Interventions

Gemcitabine 6130-nm albumin-bound paclitaxel 5Albumin-Bound Paclitaxel 4Taxes 3S 1 (combination) 3Drug Therapy 2toripalimab 1surufatinib 1paricalcitol 1nimotuzumab 1irinotecan sucrosofate 1gimeracil 1envafolimab 1endostar protein 1camrelizumab 1cabiralizumab 1apatinib 1Tegafur 1Radiosurgery 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Immunotherapy 1IMM-101 1Fluorouracil 1Endostatins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Pancreatic Cancer × paricalcitol × Clear all
NCT04617067 2024-03-06

Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer

Cancer Trials Ireland

Phase 2 Completed
15 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡